← FDA Drug Approvals (Drugs@FDA)

IMJUDO

BLA · Biologics License Application · Sponsor: ASTRAZENECA AB · Approved 2022-11-10

Drug application

FDA Application #

BLA761270

Application type

Biologics License Application

Brand name

IMJUDO

Generic name

Tremelimumab-Actl

Active ingredients

TREMELIMUMAB-ACTL

Dosage form

INJECTABLE

Route

INTRAVENOUS

Marketing status

Prescription

Sponsor

ASTRAZENECA AB

First approval

2022-11-10

Source

Authoritative

Drugs@FDA application overview

Machine

JSON-LD · Markdown